Actively Recruiting
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
Led by Korea University Anam Hospital · Updated on 2025-09-02
30
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
Sponsors
K
Korea University Anam Hospital
Lead Sponsor
D
Daewoong Pharmaceutical Co. LTD.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
CONDITIONS
Official Title
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 20 and 79 years
- Body Mass Index (BMI) of 25 kg/m² or higher, or waist circumference of at least 90 cm for males and 85 cm for females
- Diabetes with hemoglobin A1c of 6.5% or higher, or fasting blood glucose of 126 mg/dL or higher after 8 hours of fasting, or currently on antidiabetic medication with blood test results within 3 months prior to enrollment
- Patients who have undergone coronary flow velocity reserve testing
- Baseline echocardiography assessing left ventricular diastolic dysfunction structurally and hemodynamically
You will not qualify if you...
- Left ventricular ejection fraction less than 50%
- History of coronary artery disease, coronary artery intervention, or coronary artery bypass grafting
- Suspected obstructive coronary artery disease including chest pain and positive stress test results
- Second-degree or higher atrioventricular block, symptomatic bradycardia, sick sinus syndrome, or Wolff-Parkinson-White syndrome
- Chronic kidney disease with glomerular filtration rate less than 30 mL/min/1.73 m² or end-stage renal disease on dialysis
- Asthma, chronic obstructive pulmonary disease, or primary pulmonary hypertension
- Moderate or severe valvular heart disease, congenital heart disease, or history of open-heart surgery
- Active cancer within the last 5 years or currently receiving chemotherapy
- Vasculitis associated with autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis
- Unable to undergo exercise testing such as treadmill or bicycle ergometer
- Use of other SGLT2 inhibitors within the past 6 months or known allergy to these drugs
- Pregnant or breastfeeding women
- Women planning pregnancy during the study or within 24 weeks from the start of the study
- Acute urinary tract infection at enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Korea University Anam Hospital
Seoul, South Korea, 02841
Actively Recruiting
Research Team
S
So Ree Kim, MD, PhD
CONTACT
S
Seong-Mi Park, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here